KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.13
+1.28%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.09
From 52W high−36.62%
Volume952069.00
Market cap$440.94M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$7.09
From 52W high
−36.62%
Volume
952069.00
Market cap
$440.94M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
36.8
MomentumView details →
1D Return
+1.28%
YTD Return
−25.29%
SummaryUpdated Jun 1, 2026
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Emeryville, California. Originally incorporated as BAIT Therapeutics, Inc., the company changed its name to Kyverna Therapeutics in October 2019. Kyverna went public in February 2024 and focuses on developing innovative cell therapies specifically designed to treat autoimmune diseases, representing a novel approach in a field traditionally dominated by immunosuppressive drugs and biologics.
Similar companies
Latest newsMore news →
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutics' miv-cel for the treatment of non-active secondary progressive multiple sclerosis (naSPMS).40d agoKyverna Therapeutics and ElevateBio entered into a commercial manufacturing and supply agreement for Miv-cel.55d agoKyverna Therapeutics signed a Clinical and Commercial Supply Agreement with ElevateBio Basecamp for development and manufacturing services for its lead product candidate mivocabtagene autoleucel (miv-cel).56d ago